Highlights Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
3.39 ^USD	+3.04%		+10.06%	-30.82%

11/06	Transcript : Adaptive Biotechnologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM
07/05	Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q1 Revenue $41.9M, vs. Street Est of $38.8M	08/05	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Adaptive Biotechnologies Corporation Announces Preliminary Unaudited Revenue Results for the First Quarter Ended March 31, 2024	06/04	CI
Adaptive Biotechnologies Reports Preliminary Q1 Revenue, Appoints Kyle Piskel as CFO	03/04	MT
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024	03/04	CI
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down	15/02	MT
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M	15/02	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02	CI
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting	05/12	CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $37.9M, vs. Street Est of $43M	10/11	MT
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023	10/11	CI
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies	07/11	MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline	07/11	CI
Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ	13/23/13	CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts Q2 Revenue $48.9M, vs. Street Est of $44.9M	03/23/03	MT
Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2023	03/23/03	CI
Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer	02/23/02	CI
Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology	09/23/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Highlights

Filters